Gene editing: overhyped or unstoppable tide?
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Novartis stays focused
No big deals needed, executives insist, but a pipeline purge continues and analysts warn of a growth problem.
Biotech’s key upcoming clinical results
Moderna, Biomarin and Daiichi Sankyo will begin 2023 with important data reveals.
Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
